Commentary

Video

Dr Peng on the Efficacy of SHR-1701 Plus Chemotherapy in HER2– Gastric/GEJ Cancer

Author(s):

Zhi Peng, MD, discusses a study of SHR-1701 vs placebo in combination with chemotherapy in the first-line management of HER2– gastric/GEJ adenocarcinoma.

Zhi Peng, MD, associate professor, Beijing Cancer Hospital, Peking University, discusses findings from a phase 3 study (NCT04950322) of SHR-1701 vs placebo in combination with chemotherapy in the first-line treatment of patients with HER2-negative gastric/gastroesophageal junction (GEJ) adenocarcinoma.

SHR-1701 is a bifunctional agent that consists of an IgG4 monoclonal antibody targeting PD-L1 that is fused with the extracellular domain of the TGF-βIIR. This study evaluated the efficacy of adding SHR-1701 to standard chemotherapy in patients with previously untreated, unresectable, locally advanced or metastatic HER2-negative disease and was conducted in 2 parts. In part 1, the recommended dosage of SHR-1701 was established at 30 mg/kg in combination with CAPOX. Part 2 was a multicenter, randomized, double-blind study where patients were randomly assigned in a 1:1 ratio to receive chemotherapy plus either SHR-1701 at 30 mg/kg intravenously every 3 weeks or a matching placebo.

Notably, Peng and colleagues shared data from the investigation at the 2024 ESMO Congress. Between March 11, 2022, and January 13, 2024, a total of 731 patients were randomly assigned to receive either SHR-1701 plus chemotherapy (n = 365) or placebo plus chemotherapy (n = 366). As of May 20, 2024, the median follow-up duration was 8.5 months (interquartile range, 5.6-13.2). Among patients with a PD-L1 combined positive score of 5 or higher, the median overall survival (OS) was significantly longer in the SHR-1701 plus chemotherapy group compared with the placebo plus chemotherapy group at 16.8 months (95% CI, 14.7-not reached) vs 10.4 months (95% CI, 9.0-12.1 [HR, 0.53; 95% CI, 0.40-0.68; P < .0001]). In the intention-to-treat population, the median OS was also significantly higher with SHR-1701 plus chemotherapy vs placebo plus chemotherapy at 15.8 months (95% CI, 14.0-16.9) vs 11.2 months (95% CI, 9.4-12.1 [HR, 0.66; 95% CI, 0.53-0.81; P < .0001]). Additionally, progression-free survival, overall response rate, and duration of response outcomes with SHR-1701 plus chemotherapy were superior to those observed with the placebo plus chemotherapy regimen, Peng concludes.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on final overall survival data from the KEYNOTE-811 trial.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO